Evidence map›Paper›PMID 35327438›Full record

ArticleBiomedicines2022

SARS-CoV-2 mRNA Vaccine-Induced Cellular and Humoral Immunity in Hemodialysis Patients.

Ewa Kwiatkowska, Krzysztof Safranow, Iwona Wojciechowska-Koszko, Paulina Roszkowska, Violetta Dziedziejko, Marek Myślak, Jacek Różański, Kazimierz Ciechanowski, Tomasz Stompór, Jarosław Przybyciński and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Ewa KwiatkowskaClinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0002-9847-6589
Krzysztof SafranowDepartment of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0001-9415-2758
Iwona Wojciechowska-KoszkoIndependent Laboratory of Immunological Diagnostics, Department of Microbiology, Immunology and Laboratory Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.
Paulina RoszkowskaIndependent Laboratory of Immunological Diagnostics, Department of Microbiology, Immunology and Laboratory Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.
Violetta DziedziejkoDepartment of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0003-4809-415X
Marek MyślakDepartment of Nephrology and Kidney Transplantation, Provincial Integrated Hospital, Arkońska 4, 71-455 Szczecin, Poland.
Jacek RóżańskiClinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.
Kazimierz CiechanowskiClinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.
Tomasz StompórDepartment of Nephrology, Transplantology and Internal Diseases, University of Warmia and Mazury, 10-719 Olsztyn, Poland.
Jarosław PrzybycińskiClinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.
Piotr WiśniewskiClinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.
Norbert KwellaDepartment of Nephrology, Transplantology and Internal Diseases, University of Warmia and Mazury, 10-719 Olsztyn, Poland.
Sebastian KwiatkowskiDepartment of Obstetrics and Gynecology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Tomasz PrystackiFresenius Nephrocare, 60-118 Poznań, Poland.
Wojciech MarcinkowskiFresenius Nephrocare, 60-118 Poznań, Poland.
Leszek DomańskiClinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.
Pomeranian Medical University · PLUniversity of Warmia and Mazury in Olsztyn · PL

Funding

"Regional Initiative of Excellence" in 2019-2022 project number 002 / RID / 2018/19" 002 / RID / 2018/19
6 · The paper itself

Abstract

BACKGROUND/

aimsChronic kidney disease CKD patients on intermittent hemodialysis IHD are exposed to SARS-CoV-2 infection and carry a risk of developing severe symptoms. The aim of this study was to evaluate the humoral and cellular immunity induced by two doses of mRNA vaccines, the Pfizer-BioNTech (Comirnaty) COVID-19 Vaccine and the Moderna (mRNA-1273) COVID-19 vaccine. PATIENTS AND

methodsThe study included 281 patients from five dialysis centers in northern Poland. Within 2 weeks prior to the first dose of the vaccine, a blood sample was collected for an evaluation of SARS-CoV-2 antibodies. Thirty to forty-five days after the second dose of the vaccine, a blood sample was taken to evaluate humoral and cellular response.

resultsPatients with stage 5 CKD on IHD were characterized by a considerable SARS-CoV-2 vaccine-induced seroconversion rate. The strongest factors influencing the antibodies AB level after vaccination were a pre-vaccination history of SARS-CoV-2 infection, age, the neutrophil-to-lymphocyte ratio NLR, neutrophil absolute count, and the hemoglobin level. Cellular immunity was higher in patients with a pre-vaccination history of SARS-CoV-2 infection. Cellular immunity depended on the albumin level. Positive cellular response to vaccination was a positive factor reducing all-cause mortality, except for COVID-19 mortality (no such deaths were reported during our follow-up). Cellular immunity and humoral immunity were positively mutually dependent. High levels of albumin and hemoglobin, low neutrophil count, and a reduced NLR, translated into better response to vaccination.

conclusionsPatients with stage 5 CKD on IHD were characterized by a considerable SARS-CoV-2 vaccine-induced seroconversion rate and a good rate of cellular immunity. The factors that change with exacerbating inflammation and malnutrition (albumin, hemoglobin, neutrophil count, the NLR) affected the efficacy of the vaccination.

Indexed as

cellular immunityhumoral immunitymRNA vaccinationSARS-CoV-2

Identifiers

PMID35327438
PMCPMC8945424
OpenAlexW4220657848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.